explore -WSS

explore

author：fashion 2025-09-29 01:38:56 - browse：67184

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Study: Pain burden is higher in Black NFL players than white ones

hotspot

WSS

Lecanemab for Alzheimer's is coming. Is the health system ready?

BMS, looking to build heart drug business, turns to AI for diagnosis

Bird flu researchers hone in on Finland’s mink farms

Megan Rapinoe shares emotional post following US Women's World Cup exit

Dozens dead from Maui wildfires: What we know about the victims

Illinois Supreme Court finds assault weapons ban constitutional

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Retired US general questions alleged Putin, Prigozhin meeting

Moonlake's readout produced a cash windfall. Risks remain

Biden launches a new push to limit health care costs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Hollywood unions extend contract negotiations for actors

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Health AI: on the border between health care and tech

entertainment

What to know about the judge who will handle the Trump case

Beach reads and more: STAT's 2023 summer book list

Biden administration begins canceling student loan debt for 804,000 borrowers

Living with Fabry disease, a condition that causes chronic pain

Oak trusses raised to roof of fire

Why 40% Americans with Parkinson’s don’t see a neurologist

hotspot

leisure time

leisure time

explore